Previous Article | Next Article ![]()
Molecular and Cellular Biology, February 2000, p. 1149-1161, Vol. 20, No. 4
Department of Biology, Rosenstiel Basic
Medical Sciences Research Center, Brandeis University, Waltham,
Massachusetts 02454-9110
Received 7 July 1999/Returned for modification 25 August
1999/Accepted 17 November 1999
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative
disorder resulting from the neoplastic transformation of a
hematopoietic stem cell. The majority of cases of CML are associated with the (9;22) chromosome translocation that generates the
bcr-abl chimeric gene. Alpha interferon (IFN-
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Expression of Interferon Consensus Sequence Binding
Protein (ICSBP) Is Downregulated in Bcr-Abl-Induced Murine Chronic
Myelogenous Leukemia-Like Disease, and Forced Coexpression of ICSBP
Inhibits Bcr-Abl-Induced Myeloproliferative Disorder
) treatment
induces hematological remission and prolongs life in 75% of CML
patients in the chronic phase. It has been shown that mice deficient in
interferon consensus sequence binding protein (ICSBP), a member of the
interferon regulatory factor family, manifest a CML-like syndrome. We
have shown that expression of Bcr-Abl in bone marrow (BM) cells from
5-fluorouracil (5-FU)-treated mice by retroviral transduction
efficiently induces a myeloproliferative disease in mice resembling
human CML. To directly test whether icsbp can function as a
tumor suppressor gene, we examined the effect of ICSBP on
Bcr-Abl-induced CML-like disease using this murine model for CML. We
found that expression of the ICSBP protein was significantly decreased
in Bcr-Abl-induced CML-like disease. Forced coexpression of ICSBP
inhibited the Bcr-Abl-induced colony formation of BM cells from
5-FU-treated mice in vitro and Bcr-Abl-induced CML-like disease in
vivo. Interestingly, coexpression of ICSBP and Bcr-Abl induced a
transient B-lymphoproliferative disorder in the murine model of
Bcr-Abl-induced CML-like disease. Overexpression of ICSBP consistently
promotes rather than inhibits Bcr-Abl-induced B lymphoproliferation in
a murine model where BM cells from non-5-FU-treated donors were used,
indicating that ICSBP has a specific antitumor activity toward myeloid
neoplasms. We also found that overexpression of ICSBP negatively
regulated normal hematopoiesis. These data provide direct evidence that ICSBP can act as a tumor suppressor that regulates normal and neoplastic proliferation of hematopoietic cells.
*
Corresponding author. Mailing address: Rosenstiel Basic
Medical Sciences Research Center, Brandeis University, Waltham, MA 02454-9110. Phone: (781) 736-2486. Fax: (781) 736-2405. E-mail: ren{at}hydra.rose.brandeis.edu.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|